The burden of psychotropic drug prescribing in people with dementia: A population database study

Age and Ageing

Volumn 39, Issue 5, 2010, Pages 637-642

  Guthrie, Bruce ^a   Clark, Stella Anne ^b   McCowan, Colin ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

^b NHS FIFE   (United Kingdom)

Author keywords

Antipsychotic drugs; Dementia; Elderly; Family practice; Patient safety; Quality of healthcare

Indexed keywords

AMISULPRIDE; AMITRIPTYLINE; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; CHLORPROMAZINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; FLUOXETINE; HALOPERIDOL; HYPNOTIC AGENT; MIRTAZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PSYCHOTROPIC AGENT; QUETIAPINE; RISPERIDONE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGED; ANTICHOLINERGIC SYNDROME; ARTICLE; BEHAVIOR DISORDER; COMPARATIVE STUDY; CONTROLLED STUDY; DEMENTIA; DISEASE ASSOCIATION; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

AGED; AGING; DATABASES, FACTUAL; DEMENTIA; DRUG PRESCRIPTIONS; GENERAL PRACTICE; HUMANS; PHYSICIAN'S PRACTICE PATTERNS; PREVALENCE; PSYCHOTROPIC DRUGS; QUALITY OF HEALTH CARE; RETROSPECTIVE STUDIES; SCOTLAND;

EID: 77955934462     PISSN: 00020729     EISSN: 14682834     Source Type: Journal    
DOI: 10.1093/ageing/afq090     Document Type: Article

References (27)

1. Department of Health. Living Well with Dementia: A National Dementia Strategy. London: Department of Health.
2. Ballard CG, Gauthier S, Cummings JL et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurol 2009; 5: 245-55.
3. National Institute for Health and Clinical Excellence-Social Care Institute for Excellence. Dementia: A NICE-SCIE Guideline on Supporting People with Dementia and Their Carers in Health and Social Care. London: The British Psychological Society and Gaskell. 2007.
4. Ballard CG, Waite J, Birks J. Atypical antipsychotics for aggression and psychosis in Alzheimer's disease. Cochrane Database Syst Rev 2006. DOI: 10.1002/14651858.CD003476.pub2.
5. Margallo-Lana M, Swann A, O'Brien J et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatr Psychiatry 2001; 16: 39-44.
6. Committee on Safety of Medicines. Summary of Clinical Trial Data on Cerebrovascular Adverse Events (CVAEs) in Randomized Clinical Trials of Risperidone Conducted in Patients with Dementia. London: Committee on Safety of Medicines. 2004.
7. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294: 1934-43.
8. Gill SS, Bronskill SE, Normand S-L et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146: 775-86.
9. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. Can Med Assoc J 2007; 176: 627-32.
10. Rochon PA, Normand SL, Gomes T et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168: 1090-6.
11. Committee for Medicinal Products for Human Use. Opinion of the Committee for Medicinal Products for Human Use Pursuant to Article 5(3) of Regulation (EC) No 726/2004 on Conventional Antipsychotics. Brussels: European Medicines Agency. 2008.
12. Ballard C, Lana MM, Theodoulou M et al. A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Med 2008; 5: e76.
13. Ballard C, Hanney ML, Theodoulou M et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow- up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151-7.
14. Medicines and Healthcare products Regulatory Agency and Commission on Human Medicines. Drug Safety Update. 2009; vol. 2.
15. All-Party Parliamentary Group on Dementia. Always a Last Resort: Inquiry into the Prescription of Antipsychotic Drugs to People with Dementia Living in Care Homes. London: House of Commons. 2008.
16. Valiyeva E, Herrmann N, Rochon P et al. Effect of regulatory warnings on antipsychotic prescription rates among elderly patients with dementia: a population-based time-series analysis. Can Med Assoc J 2008; 179: 438-46.
17. Banerjee S. The Use of Antipsychotic Medication for People with Dementia: Time for Action. Department of Health: London. 2009.
18. Lindesay J, Matthews R, Jagger C. Factors associated with antipsychotic drug use in residential care: changes between 1990 and 1997. Int J Geriatr Psychiatry 2003; 18: 511-9.
19. Fossey J, Ballard C, Juszczak E et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ 2006; 332: 756-61.
20. Kamble P, Chen H, Sherer JT et al. Use of antipsychotics among elderly nursing home residents with dementia in the US: an analysis of National Survey Data. Drugs Aging 2009; 26: 483-92.
21. Elder R, Kirkpatrick M, Ramsay W et al. Measuring Quality in Primary Medical Services using Data from SPICE. Information and Statistics Division. Edinburgh: NHS National Services Scotland. 2007.
22. NHS England: Primary Care Commissioning. QOF Implementation: Business Rules. 2009. http://www.pcc.nhs.uk/145 (8 July 2010, date last accessed).
23. BNF. British National Formulary 54. London: BMJ Publishing Group Ltd and RPS Publishing. 2007.
24. Gray S, Lai K, Larson EB. Drug-induced cognition disorders in the elderly: incidence, prevention and management. Drug Saf 1999; 21: 101-22.
25. Berr C, Wancata J, Ritchie K. Prevalence of dementia in the elderly in Europe. Eur Neuropsychopharmacol 2005; 15: 463-71. 26.
26. Copeland JRM, Dewey ME, Wood N et al. Range of mental illness among the elderly in the community: prevalence in Liverpool using the GMS-AGECAT package. Br J Psychiatry 1987; 150: 815-23.
27. Department of Health. Government Response to Professor Sube Banerjee's Report on the Prescribing of Anti-Psychotic Drugs to People with Dementia. London: Department of Health. http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_108303 (8 July 2010, date last accessed).